Treatment at Performance Hyperbaric At Performance Hyperbaric, we understand that recovery from long COVID requires a multifaceted approach
[3] [4] In the Phase 2 trial published in the New England Journal of Medicine (2023), participants receiving retatrutide achieved substantial reductions in body weight over 24 weeks, with higher doses associated with mean weight losses of approximately 17% of body weight
As much as I love it, I wanted something that addressed deepening lip lines, uneven texture, and chronic dryness on the lips
Results showed that intranasal GHK-Cu treatment delayed cognitive impairment, reduced amyloid plaques, and lowered MCP1-mediated inflammation levels in the frontal cortex and hippocampus
The key insight is that GLP-1 medications serve as a tool to help establish new eating habits during treatment
ADA/EASD consensus reports have even proposed GLP-1 RAs as first-line injectable therapy before insulin for most T2D patients who need an injection, given the superior weight and hypoglycemia profile